Business context and reporting period
The supplied filing is Leap Therapeutics, Inc. (Nasdaq: LPTX), not Cypherpunk Technologies Inc. It is a Form 10-Q for the quarter and six months ended June 30, 2023, filed August 14, 2023. Leap is a clinical-stage biopharmaceutical company developing cancer antibody therapies. Its programs include DKN-01 and FL-301, plus preclinical FL-302 and FL-501. It reported no product sales revenue.
Financial performance and position
| Metric | Q2 2023 | Six months 2023 |
|---|---|---|
| Revenue | No product sales | No product sales |
| Research and development expense | $11.1 million | $50.0 million |
| General and administrative expense | $3.6 million | $7.3 million |
| Net loss | $13.4 million | $55.3 million |
| Basic and diluted loss per share | $0.91 | $4.01 |
| Operating cash used | Not separately stated for the quarter | $22.9 million |
At June 30, cash and cash equivalents were $91.4 million, total current assets $93.9 million, and total current liabilities $11.8 million. Total liabilities were $11.8 million, including $0.5 million in lease liabilities; the filing reports no borrowings. Stockholders’ equity was $84.1 million. The company reported an accumulated deficit of $373.4 million. No gross margin is reported; the filing does not present a clear standalone operating margin.
Material changes versus the prior comparable period
- Q2 net loss narrowed to $13.4 million from $17.0 million a year earlier. Operating expenses fell $2.2 million, mainly as manufacturing costs declined; R&D expense decreased $2.9 million, partly offset by higher clinical trial and payroll costs. Interest income rose to $1.2 million.
- For the first half, net loss increased to $55.3 million from $27.4 million. R&D expense rose $28.2 million, largely due to a $29.6 million noncash charge for acquired in-process R&D from Flame Biosciences.
- Cash rose $25.9 million from year-end to $91.4 million. The first-half investing cash inflow of $49.0 million primarily reflected $50.4 million of cash acquired with Flame, offset by acquisition costs. Operating cash use was $22.9 million.
- Shares outstanding increased from 9.9 million at December 31, 2022 to 25.6 million at June 30, 2023. The increase included consideration for the Flame transaction and conversion of Series X preferred stock; the company also effected a one-for-ten reverse stock split.
Outlook, management commentary, risks and unusual items
- Management stated that June 30 cash should fund operating expenses for at least 12 months from issuance of the financial statements. It expects continuing operating losses and may seek equity financing, government support, collaborations or licensing deals. If funding or cost-sharing is insufficient, it may delay, reduce or eliminate trials and R&D programs.
- Leap reported initial DeFianCe colorectal cancer Part A results, including an overall response rate above 20%, and said it had expanded the study to a 130-patient randomized Part B. Management expected Part B enrollment to take approximately 12 months. These are company-reported interim results; DKN-01 remains investigational.
- For the DisTinGuish gastric cancer study, the company reported two-year follow-up results from Part A: response rates of 73% in the modified intent-to-treat population and 86% in the PD-L1-low subgroup, with median overall survival of 19.5 months and progression-free survival of 11.3 months. The company described the combination as generally well tolerated. These results do not establish regulatory approval or future efficacy.
- BeiGene declined to exercise its option to license DKN-01 in March 2023; the agreement continues as a clinical collaboration. The filing cautions that clinical progress, enrollment, regulatory outcomes, financing, manufacturing, competition, and currency or supply-chain issues could affect results.
- The Flame acquisition was accounted for as an asset acquisition. Potential additional consideration may apply if specified Flame programs are sold, and certain shares were held back for indemnification claims. The company reported no material legal proceedings and $0.5 million of noncancelable manufacturing commitments at quarter-end.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing identifies Leap Therapeutics, Inc. (LPTX), not Cypherpunk Technologies Inc.
- Review cash burn assumptions behind management’s stated 12-month runway, including expected R&D spending and timing of Australian R&D incentive receipts.
- Track DeFianCe Part B enrollment and clinical endpoints, and assess the full data and limitations behind the reported DKN-01 results.
- Assess the dilution from Flame-related share issuance, the reverse split, outstanding warrants and equity awards.
- Monitor financing and collaboration prospects, as well as any contingent Flame merger consideration or indemnification claims.